AXON Axovant Sciences Ltd. Common Sh

22.91
+0.24  (1%)
Previous Close 22.67
Open 22.83
Price To book 13.50
Market Cap 2.27B
Shares 99,161,000
Volume 566,902
Short Ratio 11.40
Av. Daily Volume 715,429

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2b data due 4Q 2017
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Full study to be completed mid-2017. Phase 3 trial to be initiated 2H 2017.
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 3 data are due 3Q 2017.
Intepirdine - MINDSET
Alzheimer's disease